UOC
OACC

UBS O'Connor’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

UBS O'Connor’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.17M Hold
300,000
– – 0.08% 74
2025
Q3 		$3.15M Buy
300,000
+100,000
+50% +$1.04M 0.09% 95
2025
Q2 		$2.1M Sell
200,000
-250,000
-56% -$2.59M 0.06% 152
2025
Q1 		$4.6M Hold
450,000
– – 0.11% 70
2024
Q4 		$4.48M Buy
+450,000
New +$4.49M 0.11% 91

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

UBS O'Connor's OACC Position: Q4 2025 in Review

UBS O'Connor held its Oaktree Acquisition Corp III Life Sciences (OACC) position steady in Q4 2025 at 300,000 shares worth $3.17M. The position accounts for 0.08% of the portfolio, ranked #74.

UBS O'Connor first reported a position in OACC in Q4 2024 and has held it in 5 quarters since. The position peaked at $4.6M in Q1 2025. 49 funds tracked by Wall St. Rank hold OACC as of Q4 2025.

  • UBS O'Connor held 300,000 shares of Oaktree Acquisition Corp III Life Sciences worth $3.17M as of Q4 2025.
  • UBS O'Connor left its Oaktree Acquisition Corp III Life Sciences share count unchanged in Q4 2025.
  • Oaktree Acquisition Corp III Life Sciences made up 0.08% of UBS O'Connor's portfolio in Q4 2025, its #74 holding.
  • UBS O'Connor first reported a position in Oaktree Acquisition Corp III Life Sciences in Q4 2024 and has held it in 5 quarters since.
  • UBS O'Connor's Oaktree Acquisition Corp III Life Sciences position peaked at $4.6M in Q1 2025.
  • 49 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q4 2025.

Based on UBS O'Connor's 13F filing for Q4 2025, filed 13 Feb 2026.